Weekly Investment Analysts’ Ratings Changes for Gilead Sciences (GILD)

Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

• 11/4/2025 – Gilead Sciences had its price target raised by analysts at Argus from $130.00 to $135.00. They now have a “buy” rating on the stock.
• 11/3/2025 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.
• 11/3/2025 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $145.00 price target on the stock, up previously from $127.00.
• 10/31/2025 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $145.00 to $150.00. They now have an “overweight” rating on the stock.
• 10/31/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank Of Canada from $100.00 to $105.00. They now have a “sector perform” rating on the stock.
• 10/31/2025 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
• 10/31/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $140.00 to $145.00. They now have an “overweight” rating on the stock.
• 10/31/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $143.00 to $147.00. They now have an “overweight” rating on the stock.
• 10/31/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $108.00 to $110.00. They now have a “neutral” rating on the stock.
• 10/31/2025 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 10/23/2025 – Gilead Sciences had its price target raised by analysts at TD Cowen from $115.00 to $125.00. They now have a “buy” rating on the stock.
• 10/23/2025 – Gilead Sciences had its price target raised by analysts at Wolfe Research from $135.00 to $140.00. They now have an “outperform” rating on the stock.
• 10/20/2025 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $130.00 to $135.00. They now have an “outperform” rating on the stock.
• 10/17/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $108.00. They now have a “neutral” rating on the stock.
• 10/9/2025 – Gilead Sciences had its price target raised by analysts at Cantor Fitzgerald from $129.00 to $135.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Gilead Sciences had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank Of Canada from $98.00 to $100.00. They now have a “sector perform” rating on the stock.
• 10/8/2025 – Gilead Sciences had its price target raised by analysts at Citigroup Inc. from $125.00 to $135.00. They now have a “buy” rating on the stock.
• 9/27/2025 – Gilead Sciences had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 9/16/2025 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $145.00. They now have an “overweight” rating on the stock.
• 9/12/2025 – Gilead Sciences had its price target raised by analysts at Rothschild & Co Redburn from $136.00 to $143.00. They now have a “buy” rating on the stock.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.